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A bs tr ac t
Background
Microalbuminuria is an early predictor of diabetic nephropathy and premature car-
diovascular disease. We investigated whether treatment with an angiotensin-receptor 
blocker (ARB) would delay or prevent the occurrence of microalbuminuria in pa-
tients with type 2 diabetes and normoalbuminuria.
Methods
In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 pa-
tients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or 
placebo for a median of 3.2 years. Additional antihypertensive drugs (except angio-
tensin-converting–enzyme inhibitors or ARBs) were used as needed to lower blood 
pressure to less than 130/80 mm Hg. The primary outcome was the time to the first 
onset of microalbuminuria. The times to the onset of renal and cardiovascular 
events were analyzed as secondary end points.
Results
The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the pa-
tients taking olmesartan and 71% taking placebo; blood pressure measured in the 
clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group. 
Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 
2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139); 
the time to the onset of microalbuminuria was increased by 23% with olmesartan 
(hazard ratio for onset of microalbuminuria, 0.77; 95% confidence interval, 0.63 to 
0.94; P = 0.01). The serum creatinine level doubled in 1% of the patients in each 
group. Slightly fewer patients in the olmesartan group than in the placebo group 
had nonfatal cardiovascular events — 81 of 2232 patients (3.6%) as compared with 
91 of 2215 patients (4.1%) (P = 0.37) — but a greater number had fatal cardiovascular 
events — 15 patients (0.7%) as compared with 3 patients (0.1%) (P = 0.01), a differ-
ence that was attributable in part to a higher rate of death from cardiovascular 
causes in the olmesartan group than in the placebo group among patients with pre-
existing coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P = 0.02).
Conclusions
Olmesartan was associated with a delayed onset of microalbuminuria, even though 
blood-pressure control in both groups was excellent according to current standards. 
The higher rate of fatal cardiovascular events with olmesartan among patients with 
preexisting coronary heart disease is of concern. (Funded by Daiichi Sankyo; 
ClinicalTrials.gov number, NCT00185159.)
The New England Journal of Medicine 
Downloaded from nejm.org on September 19, 2011. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 364;10 nejm.org march 10, 2011908
Diabetic nephropathy is an increas-ingly common cause of end-stage renal disease,1 and the development and rate of 
renal deterioration are most closely related to the 
patient’s blood pressure. Guideline committees 
worldwide concur that the blood pressure in pa-
tients with diabetes and chronic kidney disease 
should be kept at 130/80 mm Hg or less.2 Micro-
albuminuria is predictive of diabetic nephropathy 
and premature cardiovascular disease3-5; there-
fore, European and American guidelines recom-
mend that patients with diabetes be tested for 
microalbuminuria.6,7
Overactivity of the renin–angiotensin system 
has been implicated in the deterioration of renal 
function in patients with diabetic nephropathy 
and in patients who have stage 3 or 4 chronic 
kidney disease with microalbuminuria or macro-
albuminuria.8,9 Angiotensin-converting–enzyme 
(ACE) inhibitors and angiotensin-receptor block-
ers (ARBs) slow the worsening of the glomerular 
filtration rate (GFR) and lower the rate of albumin 
excretion. Treatment at an early stage of the dis-
ease may be beneficial. ACE inhibition delays the 
onset of microalbuminuria in patients with hy-
pertension, type 2 diabetes, normoalbuminuria, 
and normal renal function.10 Whether similar 
benefits occur when ARB therapy is begun early 
in the course of diabetes is unknown.11,12
In the Randomized Olmesartan and Diabetes 
Microalbuminuria Prevention (ROADMAP) study, 
we tested whether olmesartan medoxomil (Beni-
car, Daiichi Sankyo), at a dose of 40 mg daily, as 
compared with placebo, prevents or delays the 
time to the first occurrence of microalbuminuria 
in patients who have type 2 diabetes, as well as 
at least one other cardiovascular risk factor, 
and normoalbuminuria. Blood-pressure control 
(<130/80 mm Hg) in both groups was achieved 
by adding, as needed, antihypertensive agents 
that do not block the renin–angiotensin system.
Me thods
Study Design and Organization
The study design has been published previously.13 
The sponsor (Daiichi Sankyo) had no role in the 
design or conduct of the study, but representa-
tives of the sponsor served as nonvoting members 
of the steering committee. Statistical analyses 
were performed by a clinical research organiza-
tion, with confirmation by biostatisticians who 
were employees of the sponsor. The authors had 
complete control over the analysis and interpreta-
tion of the results, the writing of the manuscript, 
and the decision to submit it for publication, and 
they vouch for the accuracy and completeness of 
the reported data, as well as the fidelity of the 
reported study to the protocol. The study protocol, 
including the statistical analysis plan, is available 
with the full text of this article at NEJM.org.
We conducted this randomized, double-blind, 
placebo-controlled, parallel-group, multicenter 
phase 3b study at 262 collaborating centers in 19 
European countries. The ethics committee at each 
participating center approved the study, and writ-
ten informed consent was obtained from each 
patient. The study enrolled patients with type 2 
diabetes, among whom there was a wide range of 
blood-pressure values, including some that were 
in the normal range. Patients who had used ACE 
inhibitors or ARBs during the 6 months before 
the start of the study were excluded. Treatment 
with ACE inhibitors and ARBs (other than olme-
s artan in the experimental group) was not allowed 
at any time during the study; during the double-
blind treatment phase, other antihypertensive 
agents were allowed in both groups to help pa-
tients reach and maintain the target blood pres-
sure of less than 130/80 mm Hg.
Study Population
A total of 4449 white patients, 18 to 75 years of 
age, who had type 2 diabetes underwent random-
ization. A summary of the main inclusion and 
exclusion criteria and an overview of the screen-
ing, enrollment, randomization, and follow-up 
are shown in Tables 1 and 2 in the Supplemen-
tary Appendix, available at NEJM.org. After the 
screening phase, each patient’s eligibility for the 
study was established during a prerandomiza-
tion phase (maximum duration, 4 weeks), dur-
ing which normoalbuminuria was confirmed by 
means of two additional measurements of morn-
ing spot urine samples.
End Points
The primary end point was the time to the first 
onset of microalbuminuria, as determined by vali-
dated measurements of morning spot urine sam-
ples. Microalbuminuria was defined as a urinary 
albumin-to-creatinine ratio (with albumin mea-
sured in milligrams and creatinine measured in 
grams) of more than 35 in women or more than 
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25 in men. Any single elevation in the urinary 
albumin-to-creatinine ratio required confirma-
tion by at least one additional positive result from 
two separate tests of urine samples performed 
within 2 weeks after the initial test. If microalbu-
minuria was confirmed, the patient was assigned 
to an open-label phase in which he or she received 
olmesartan at a dose of 40 mg daily (Fig. 1 in the 
Supplementary Appendix). At each follow-up vis-
it, a spot urine sample was obtained, and blood 
pressure was measured with an automatic device. 
The blood-pressure measurement that was used 
was the mean of three values recorded 3 minutes 
apart. If the blood pressure was 130/80 mm Hg or 
higher, the protocol called for adjustment of the 
antihypertensive medication (excluding the use of 
blockers of the renin–angiotensin system or aldo-
sterone blockers). A central laboratory (CRL-Medi-
net) determined the urinary albumin-to-creatinine 
ratio and all other laboratory variables. Second-
ary end points included a composite of cardio-
vascular complications and death from cardio-
vascular causes (Table 3 in the Supplementary 
Appendix) and renal events.
Statistical Analysis
A total of 4447 of the 4449 patients who under-
went randomization were included in the inten-
tion-to-treat analysis; 2 patients who underwent 
randomization never took a study medication 
(Table 2A in the Supplementary Appendix). The 
baseline urinary albumin-to-creatinine ratio was 
the geometric mean of three measurements ob-
tained during the randomization phase (up to 
visit 1). A confirmatory analysis of the primary 
efficacy end point was performed with the use of 
a Cox proportional-hazards regression model with 
treatment as a fixed effect; the baseline urinary 
albumin-to-creatinine ratio was logarithmically 
transformed (base 10) as a covariate, and a two-
tailed Wald chi-square test was performed with 
an alpha level of less than 0.05; hazard ratios and 
two-sided 95.1% confidence intervals were calcu-
lated. (Owing to a prespecified interim analysis 
performed by the data and safety monitoring 
board, the significance level for the final confir-
matory analysis was adjusted to 0.049, resulting 
in a two-sided 95.1% confidence interval.) To ac-
count for all patients who entered the double-
blind treatment period, the last assessment that 
was performed before patients left the double-
blind period was used as the last time point. All 
statistical analyses were performed with the use 
of SAS software for Windows, version 9.1.3 (SAS 
Institute); values are expressed as means ±SD un-
less otherwise indicated. Section 1 in the Supple-
mentary Appendix includes additional informa-
tion regarding the calculation of the sample size 
and other statistical methods.
R esult s
Study Patients
Recruitment began in October 2004 and was 
completed in May 2006. After the prespecified 
number of adjudicated microalbuminuria events 
was reached, the study was stopped. The last 
evaluation for any patient occurred in June 2009; 
the median follow-up period was 3.2 years. The 
baseline data for participants are summarized in 
Table 1. The mean duration of diabetes was 6.1 
years, and the mean glycated hemoglobin level 
was 7.7%. More than 97% of the patients had at 
least two cardiovascular risk factors in addition 
to type 2 diabetes, and 67.7% had at least four.
Blood-Pressure Control
The mean blood pressure during the follow-up 
period was 125.7/74.3 mm Hg in the olmesartan 
group and 128.7/76.2 mm Hg in the placebo group 
(Fig. 2A in the Supplementary Appendix). Nearly 
80% of the patients in the olmesartan group and 
about 71% of the patients in the placebo group 
had a blood pressure of less than 130/80 mm Hg 
(the target) at month 48 (Fig. 2B in the Supple-
mentary Appendix).
At the end of the study, 24-hour ambulatory 
blood-pressure monitoring was performed in 
568 patients (270 in the olmesartan group and 
298 in the placebo group). Over the course of the 
study, blood pressure, as measured both in the 
clinic and by means of 24-hour ambulatory 
blood-pressure monitoring, was lower in the ol-
mesartan group than in the placebo group (by 
3.3/1.3 mm Hg in clinic measurements and by 
3.5/1.2 mm Hg with 24-hour ambulatory blood-
pressure monitoring).
Primary End Point
During the double-blind treatment period, mi-
croalbuminuria developed in 178 of 2160 patients 
in the olmesartan group for whom measurements 
of urinary albumin-to-creatinine ratio could be 
evaluated (8.2%) and 210 of 2139 patients in the 
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placebo group for whom measurements of uri-
nary albumin-to-creatinine ratio could be evalu-
ated (9.8%); the median time to the onset of mi-
croalbuminuria was 576 days in the placebo 
group and 722 days in the olmesartan group. The 
primary end point, the time to the onset of 
 microalbuminuria (Fig. 1), was increased by 23% 
with olmesartan (hazard ratio for onset of micro-
albuminuria, 0.77; 95.1% confidence interval [CI], 
0.63 to 0.94; P = 0.01). After adjustment for small 
baseline differences in the body-mass index, sys-
tolic blood pressure, and levels of high-density 
lipoprotein cholesterol and triglycerides (Table 
1), the hazard ratio for the primary end point was 
0.75 (95.1% CI, 0.62 to 0.92; P = 0.006). Similar 
results were obtained in a prespecified per-proto-
col analysis and in a post hoc analysis that ex-
cluded patients who discontinued the study treat-
ment prematurely (Table 4 in the Supplementary 
Appendix). The reduction in the primary end point 
with olmesartan remained after adjustment for 
differences in blood-pressure levels (Fig. 2). To 
identify other factors influencing the response to 
olmesartan treatment, an exploratory post hoc 
subgroup analysis was performed for several 
known risk factors, with dichotomization at the 
median for each candidate predictor variable. 
Baseline characteristics associated with a favor-
able response to olmesartan therapy included sys-
tolic blood pressure higher than 135 mm Hg, 
a glycated hemoglobin level of 7.3% or less, an es-
timated GFR of 83.79 ml per minute per 1.73 m2 of 
body-surface area or less, and a urinary albumin-
to-creatinine ratio of more than 4 (Fig. 2).
Secondary End Points
Renal Function
The mean estimated GFR declined from 85.0±17.0 
ml per minute per 1.73 m2 at baseline to 80.1±18.5 
ml per minute per 1.73 m2 at the last assessment 







(N = 4447) P Value
Male sex — no. (%) 1049 (47.0) 1003 (45.3) 2052 (46.1) 0.25†
Age
Mean — yr 57.7±8.8 57.8±8.6 57.7±8.7 0.74‡
≥65 yr — no. (%) 564 (25.3) 554 (25.0) 1118 (25.1) 0.84†
Body-mass index§ 31.1±4.9 30.9±4.9 31.0±4.9 0.05‡
Diabetes
Duration — yr 6.2±6.0 6.1±6.0 6.1±6.0 0.60‡
Prior treatment — no. (%) 2072 (92.8) 2069 (93.4) 4141 (93.1) 0.45†
Smoking status — no. (%) 0.91†
Never smoked 1367 (61.2) 1343 (60.6) 2710 (60.9)
Former smoker 452 (20.3) 453 (20.5) 905 (20.4)
Current smoker 413 (18.5) 419 (18.9) 832 (18.7)
Metabolic syndrome — no. (%)¶ 1834 (82.2) 1797 (81.1) 3631 (81.7) 0.37†
Cardiovascular history — no. (%)
Coronary heart disease 564 (25.3) 540 (24.4) 1104 (24.8) 0.49†
Myocardial infarction 134 (6.0) 119 (5.4) 253 (5.7) 0.36†
Stroke or TIA 55 (2.5) 49 (2.2) 104 (2.3) 0.58†
Peripheral vascular disease 17 (0.8) 8 (0.4) 25 (0.6) 0.07†
Glucose — mmol/liter 9.0±3.1 9.0±3.1 9.0±3.1 1.00‡
Glycated hemoglobin — % 7.7±1.6 7.7±1.6 7.7±1.6 0.89‡
Blood pressure while seated — mm Hg
Systolic 137±16 136±15 136±15 0.02‡
Diastolic 81±10 80±9 81±10 0.11‡
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in the olmesartan group and from 84.7±17.3 ml 
per minute per 1.73 m2 to 83.7±18.3 ml per min-
ute per 1.73 m2 in the placebo group (P<0.001 for 
the between-group comparison of the change 
from baseline). End-stage renal disease did not 
develop in any patient; the number of patients in 
whom there was a doubling of the serum creati-
nine level was the same in each group (23 pa-
tients, or approximately 1%).
Cardiovascular End Points
The proportion of patients who reached the com-
posite end point of cardiovascular complications 
or death from cardiovascular causes was similar 
in the two groups — 96 of 2232 patients (4.3%) 
in the olmesartan group and 94 of 2215 patients 
(4.2%) in the placebo group (Table 2). The rate of 
death from any cause was also very low — 1.2% 
(26 deaths) among patients taking olmesartan 
and 0.7% (15) among patients taking placebo 
(P = 0.10); in no case did the investigator report 
that the death was related to the study medica-
tion. The number of deaths from cardiovascular 
causes was higher in the olmesartan group than 
in the placebo group (15 vs. 3, P = 0.01) (Table 2), 
owing primarily to more cases of fatal myocar-
dial infarction (5 vs. 0) and sudden cardiac deaths 
(7 vs. 1) in the olmesartan group. The majority of 
deaths from cardiovascular causes (12 of 18) oc-
curred in the subgroup of 1104 patients who had 
preexisting coronary heart disease. A post hoc 
analysis revealed an interaction between study 
group and preexisting coronary heart disease; 
among patients with preexisting coronary heart 
disease, there were 11 deaths from cardiovascu-
lar causes in the olmesartan group as compared 
with 1 in the placebo group (6.9 vs. 0.7 events per 
1000 person-years, P = 0.02) (Table 5 in the Sup-
plementary Appendix). A further exploratory analy-








(N = 4447) P Value
Urinary albumin-to-creatinine ratio‖
Geometric mean 6.3±7.6 5.9±6.7 6.1±7.2 0.06‡
Median 4 3 4
Interquartile range 2–7 2–7 2–7
Serum creatinine — μmol/liter 77.4±15.2 77.5±17.1 77.5±16.2 0.96‡
Estimated GFR**
Mean — ml/min/1.73 m2 85.0±17.0 84.7±17.3 84.9±17.2 0.60‡
<60 ml/min/1.73 m2 — no. (%) 138 (6.2) 120 (5.4) 258 (5.8) 0.28†
Cholesterol — mmol/liter
Total 5.2±1.1 5.2±1.1 5.2±1.1 0.76‡
LDL 3.1±0.9 3.1±0.9 3.1±0.9 0.31‡
HDL 1.20±0.30 1.22±0.30 1.21±0.30 0.02‡
Triglycerides — mmol/liter 2.1±1.7 2.0±1.3 2.1±1.5 0.02‡
*  Plus–minus values are means ±SD. To convert the values for glucose to milligrams per deciliter, divide by 0.05551. 
To convert the values for creatinine to milligrams per deciliter, divide by 88.4. To convert the values for cholesterol to 
milligrams per deciliter, divide by 0.02586. To convert the values for triglycerides to milligrams per deciliter, divide by 
0.01129. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and TIA transient ischemic attack.
†  Exploratory comparisons were performed with the use of a chi-square test.
‡  Exploratory comparisons were performed with the use of Student’s t-test.
§  The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶  The metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
‖  Albumin was measured in milligrams, and creatinine in grams. The baseline urinary albumin-to-creatinine ratio was 
defined as the geometric mean of the last three measurements that could be evaluated at the time of visit 1 (baseline). 
If insufficient measurements were available at baseline, the last measurements from the screening period were used.
** The estimated glomerular filtration rate (GFR) was calculated with the use of the abbreviated Modification of Diet in 
Renal Disease formula.
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tients with preexisting coronary heart disease, 
those in the lowest quartile of systolic blood pres-
sure and those in the highest quartile of reduc-
tion in systolic blood pressure during the double-
blind treatment period had the highest rates of 
death from cardiovascular causes (Fig. 3 in the 
Supplementary Appendix). No interactions with 
diastolic blood pressure were detected. The rate of 
nonfatal cardiac events was reduced with olmes-
artan as compared with placebo among patients 
without preexisting coronary heart disease but 
not among those with preexisting coronary heart 
disease (Table 5 in the Supplementary Appendix).
Adverse Events
The number of participants in whom adverse 
events occurred during the treatment period was 
similar in the two groups (Table 3). Serious ad-
verse events were reported in 335 patients (15.0%) 
in the olmesartan group and 337 (15.2%) in the 
placebo group. Drug-related adverse events oc-
curred in 255 patients (11.4%) receiving olmesar-
tan and 166 (7.5%) receiving placebo (P<0.001). 
This difference was due in part to a higher rate 
in the olmesartan group than in the placebo group 
of hypotension (58 patients vs. 6, P<0.001) and 
dizziness (103 vs. 61, P = 0.001). More patients in 
the olmesartan group than in the placebo group 
were withdrawn from the study because of symp-
tomatic hypotensive episodes (10 patients vs. 1).
Discussion
There is convincing epidemiologic evidence that 
in patients with diabetes who also have microal-
buminuria, renal impairment and cardiovascular 
events occur earlier than they do in patients with 
diabetes who do not have microalbuminuria.14-16 
In this study, ARB-based therapy in patients with 
type 2 diabetes increased the time to the onset of 
microalbuminuria by 23%. The baseline charac-
teristics of patients who were most likely to ben-
efit from ARB therapy included a higher systolic 
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Figure 1. Occurrence of Microalbuminuria during the 48-Month Follow-up Period in the Two Study Groups.
The restricted full analysis set was used for this analysis. This set comprises all patients from the full analysis set 
(i.e., patients in the intention-to-treat population) with the exception of patients who had confirmed microalbuminuria 
at baseline (visit 1) and patients without any follow-up measurements of microalbuminuria that could be evaluated.
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better control of diabetes (glycated hemoglobin 
levels of ≤7.3 mg per deciliter), a lower level of 
renal function (estimated GFR of <84 ml per min-
ute per 1.73 m2), and a urinary albumin-to-crea-
tinine ratio of more than 4. During the double-
blind treatment period, systolic and diastolic blood 
pressures were lower in the olmesartan group 
than in the placebo group by approximately 
3.1/1.9 mm Hg.
Our findings extend the results of the Ber-
gamo Nephrologic Diabetes Complications Trial 
(BENEDICT),10 in which ACE inhibition with 
trandolapril was associated with a 53% decrease 
in the rate of microalbuminuria in patients with 
hypertension and type 2 diabetes. The greater 
treatment effect in BENEDICT is probably due to 
higher baseline and follow-up blood pressures; 
a post hoc analysis showed that the benefit oc-
curred in patients with a systolic blood pressure 
higher than 139 mm Hg during follow-up.17 The 
mean baseline blood pressure in the ROADMAP 
study was 136/81 mm Hg, and the target blood 
pressure (<130/80 mm Hg) was achieved by month 
48 in nearly 80% of the patients taking olmesar-
tan and 71% of those taking placebo. In both 
groups, antihypertensive drugs other than block-
ers of the renin–angiotensin system were added 
as needed. In contrast, only 14% of the subjects 
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Figure 2. Event Rate of the Primary End Point in the Two Study Groups, According to Subgroups.
The restricted full analysis set was used for this analysis. This set comprises all patients from the full analysis set (i.e., patients in the  
intention-to-treat population) with the exception of patients who had confirmed microalbuminuria at baseline (visit 1) and patients with-
out any follow-up measurements of microalbuminuria that could be evaluated. All the results are based on adjudicated end points. The 
primary efficacy end point (the time to the onset of microalbuminuria) was analyzed with the use of a Cox proportional-hazards regres-
sion model, with study treatment as the fixed effect and the log10-transformed baseline urinary albumin-to-creatinine ratio (with albu-
min measured in milligrams and creatinine measured in grams) as the covariate. Owing to a prespecified interim analysis performed by 
the data and safety monitoring board, the significance level for the final confirmatory analysis was adjusted to 0.049, resulting in a two-
sided 95.1% confidence interval. For all other analyses, two-sided 95% confidence intervals are shown. The sensitivity analyses were per-
formed by extending the main model by an additional covariate. The exploratory subgroup analyses were performed with the use of the 
main model, with the exception of the subgroup analysis of urinary albumin-to-creatinine ratio. In this last analysis, the Cox proportional-
hazards regression model with study treatment as the fixed effect was used.
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in BENEDICT reached this level of blood-pressure 
control.17 The results of the current study also 
differ somewhat from those of the Renin–Angio-
tensin System Study (RASS; ClinicalTrials.gov 
number, NCT00143949)12 and the Diabetic Reti-
nopathy Candesartan Trials (DIRECT; Clinical 
Trials.gov numbers, NCT00252733, NCT00252720, 
and NCT00252694),11 which did not show a pro-
tective effect of ARBs or ACE inhibitors against 
the development of microalbuminuria in patients 
with type 1 diabetes and in patients with type 2 
diabetes, respectively, despite a substantial reduc-
tion in blood pressure. In both of these studies, 
the baseline systolic blood pressure was quite low 
— 133 mm Hg in DIRECT-Renal and 120 mm Hg 
in RASS.11 Other studies, such as the Heart Out-
comes and Prevention Evaluation (HOPE),18 the 
Telmisartan Randomised Assessment Study in 
ACE Intolerant Subjects with Cardiovascular Dis-
ease (TRANSCEND; NCT00153101),19 and the 
Action in Diabetes and Vascular Disease: Preterax 
and Diamicron-MR Controlled Evaluation study 
(ADVANCE; NCT00145925),20 had previously re-
ported a positive relation between baseline sys-
tolic blood pressure and microalbuminuria. Thus, 
overall, it appears that the higher the baseline 
blood pressure, the greater the potential bene-
fit of an inhibitor of the renin–angiotensin sys-
tem.10,11,18-20
The greater tendency for patients with a lower 
estimated GFR (<83.8 ml per minute per 1.73 m2) 
or a urinary albumin-to-creatinine ratio at the high 
end of the normal range (>4) to have a great er 
benefit with olmesartan is also of potential inter-
est. This trend was also seen in TRANSCEND19 
and may help to identify patients with type 2 
diabetes and no microalbuminuria who might 
be potential candidates for ARB therapy.
Changes in the GFR were minimal over the 
course of the study; olmesartan was associated 







(95% CI) P Value
no. of patients (%)
Composite of cardiovascular complications or death from  
cardiovascular causes
96 (4.3) 94 (4.2) 1.00 (0.75–1.33) 0.99
Composite of death from any cause 26 (1.2) 15 (0.7) 1.70 (0.90–3.22) 0.10
Death from cardiovascular causes 15 (0.7) 3 (0.1)
Death not related to cardiovascular causes 8 (0.4) 10 (0.5)
Death from unknown cause 3 (0.1) 2 (0.1)
Composite of death from cardiovascular causes 15 (0.7) 3 (0.1) 4.94 (1.43–17.06) 0.01
Sudden cardiac death 7 (0.3) 1 (<0.1)
Death due to fatal myocardial infarction 5 (0.2) 0
Evidence of recent myocardial infarction on autopsy 0 0
Death due to congestive heart failure 0 0
Death during or after percutaneous transluminal coronary 
angioplasty or CABG
1 (<0.1) 0
Death due to fatal stroke 2 (0.1) 2 (0.1)
Composite of cardiovascular complications, excluding new- 
onset atrial fibrillation and transient ischemic attack
63 (2.8) 71 (3.2) 0.87 (0.62–1.22) 0.42
Composite of new-onset atrial fibrillation or transient isch-
emic attack
19 (0.9) 28 (1.3) 0.67 (0.37–1.19) 0.17
Composite of all cardiovascular complications 81 (3.6) 91 (4.1) 0.87 (0.65–1.18) 0.37
* All results were based on adjudicated end points. The composite secondary efficacy end points were analyzed with the 
use of a Cox proportional-hazards regression model with study treatment as the fixed effect. For composite end points, 
the time to the onset of an event was defined as the time from randomization (date of visit 1) to the first occurrence of 
any component of the composite end point. CABG denotes coronary-artery bypass grafting.
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with a slight but significant reduction in the esti-
mated GFR (about 4 ml per minute per 1.73 m2), 
whereas an even smaller decrease in the estimat-
ed GFR was noted in patients treated with agents 
that do not block the renin–angiotensin system. 
It is reassuring that the rate of renal events (de-
fined as a doubling of the serum creatinine level 
or the need for dialysis) was low and was identi-
cal in the olmesartan and placebo groups. There 
was no washout period at the end of the study, 
so we can only speculate about whether the drop 
in the estimated GFR and the lower rate of micro-
albuminuria in the olme sartan group represent a 
favorable hemodynamic (functional) response to 
lower glomerular pressure or an adverse under-
lying structural change. Recent studies suggest 
that a low estimated GFR and microalbuminuria 
are independent prognostic markers.14,15,21 In a 
meta-analysis,21 an estimated GFR below 60 ml 
per minute per 1.73 m2 was predictive of death 
from any cause and of death from cardiovascular 
causes, but as in the present trial, there was no 
relationship to the risk of cardiovascular disease 
when the estimated GFR was 75 to 104 ml per 
minute per 1.73 m2. This supports the notion that 
in patients with diabetes, the observed change in 
the rate of microalbuminuria might in the long-
term be of greater importance than the small 
fall in the estimated GFR.
The rates of cardiovascular and cerebrovascu-
lar events in the present study were low (about 
4%, or 2.9 cases per 1000 person-years); they 
were similar to those in BENEDICT but lower 
than those in DIRECT-2 (8.0 cases per 1000 per-
son years)10,11 and substantially lower than those 
in studies involving patients with more advanced 
renal disease, such as the Reduction of End-
points in NIDDM with the Angiotensin II Antago-
nist Losartan (RENAAL) study and the Irbesartan 
Diabetes Nephropathy Trial (IDNT), in which the 
rates were higher by a factor of approximately 20, 
or 60 cases per 1000 person-years.8,9 
Despite the low rates of cardiovascular events, 
there were more deaths from cardiovascular causes 
in the olmesartan group than in the placebo group 
(15 vs. 3, P = 0.01). Owing to the very small num-
ber of affected patients, it is difficult to interpret 
this unexpected finding, and it may simply be 
related to chance. Nevertheless, because of its 
potential significance, several exploratory analy-
ses were performed. Fatal cardiovascular events 
were more common in the olmesartan group 
than in the placebo group among patients with 
known preexisting coronary heart disease (11 
events vs. 1 with placebo, P = 0.03), but the rates 
were similar in the two groups among patients 
without preexisting coronary disease. There was 
also a trend toward more fatal events in patients 
with preexisting coronary heart disease who 
were either in the lowest quartile of blood pres-
sure or in the highest quartile of blood-pressure 
reduction during follow-up. Therefore, excessive 
reduction of blood pressure in some high-risk 
patients may confer a predisposition to an in-
creased risk of death, a finding that is consis-
tent with the well-known, somewhat controversial 
“J-curve effect”; however, a direct effect of olme-
sartan cannot be ruled out. 
In the Olmesartan Reducing Incidence of 
End Stage Renal Disease in Diabetic Nephropa-
thy Trial (ORIENT; NCT00141453), which involved 





(N = 2215) P Value*
no. of patients (%)
At least one serious event 335 (15.0) 337 (15.2) 0.85
At least one drug-related event† 255 (11.4) 166 (7.5) <0.001
At least one serious drug-related event 4 (0.2) 1 (<0.1) 0.18
Most frequently reported events‡
Hypertension 164 (7.3) 178 (8.0) 0.39
Headache 100 (4.5) 153 (6.9) <0.001
Nasopharyngitis 112 (5.0) 94 (4.2) 0.22
Bronchitis 102 (4.6) 104 (4.7) 0.22
Influenza 80 (3.6) 98 (4.4) 0.15
Back pain 96 (4.3) 75 (3.4) 0.11
Dizziness 103 (4.6) 61 (2.8) 0.001
Peripheral edema 60 (2.7) 86 (3.9) 0.03
Events of special interest
Hypotension 58 (2.6) 6 (0.3) <0.001
Hyperkalemia 11 (0.5) 8 (0.4) 0.50
* P values were calculated with the use of a chi-square test.
† An event was considered to be drug-related if, according to the investigator’s 
judgment, the event was definitely, probably, or possibly related to the treat-
ment or if information on the relationship of the event to the study treatment 
was missing.
‡ Events included in this category are those that occurred in at least 3% of the 
patients in either study group; adverse events that were part of the primary or 
secondary efficacy end points are not shown.
The New England Journal of Medicine 
Downloaded from nejm.org on September 19, 2011. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 364;10 nejm.org march 10, 2011916
patients with diabetic nephropathy, the addition 
of olmesartan to preexisting antihypertensive 
treatment was associated with a higher rate of 
death from cardiovascular causes (10 cases vs. 3 
cases; www.fda.gov/Drugs/DrugSafety/Postmarket 
DrugSafetyInformationforPatientsandProviders/ 
ucm215222.htm). Because of these findings in 
ROADMAP and ORIENT, the Food and Drug Ad-
ministration is currently reviewing existing data. 
Nevertheless, the rate of nonfatal cardiovascular 
events was not increased with olmesartan among 
patients without preexisting coronary heart dis-
ease. The results of the current study must also 
be viewed in the context of the many other stud-
ies of renal and cardiovascular outcomes that 
have shown that ARBs have a beneficial effect on 
cardiovascular disease.22,23
In the Ongoing Telmisartan Alone and in Com-
bination with Ramipril Global Endpoint Trial 
(ONTARGET; NCT00153101)24 and the Interna-
tional Verapamil SR Trandolapril Study (INVEST; 
NCT00133692),25 an increase in the rate of death 
from cardiovascular causes was observed among 
patients with known coronary heart disease if the 
systolic blood pressure was below 120 mm Hg 
during the time the patient was receiving therapy 
with ACE inhibitors or ARBs (in ONTARGET) or 
calcium-channel blockers or beta-blockers (in 
INVEST); thus, any adverse effect appears to be 
related more closely to the achieved blood pres-
sure than the class of drug that was used. The 
concern about potential overtreatment is reflected 
in the guidelines published by the European Soci-
ety of Hypertension, which state that physicians 
should avoid lowering blood pressure excessively 
(i.e., to values below 120/70 mm Hg) in persons 
with underlying cardiovascular disease.26
Our study has certain limitations. First, it is 
not possible to draw definite conclusions from a 
short-term prevention study about the way in 
which changes in microalbuminuria may affect 
the rates of renal and cardiovascular event rates 
in the long term. During the study itself, the 
follow-up period was too short. Second, the rate 
of premature withdrawals in both study groups 
was high (about 23% in both groups); however, 
it seems unlikely that withdrawals affected the 
overall findings of the study, since an exploratory 
analysis excluding these patients did not affect 
the primary end point. Third, although the differ-
ences in blood pressure between the treatment 
groups may have contributed to the primary out-
come, and the benefit was greater in patients with 
higher baseline blood pressure, adjustment of the 
analysis for differences in blood pressure during 
the study did not eliminate the improvement in the 
primary end point that was seen with olmesartan.
In summary, this trial suggests that olmesar-
tan increases the time to the onset of microal-
buminuria in patients with type 2 diabetes, even 
when blood-pressure control is excellent accord-
ing to current recommendations.
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